Taivex’s anti-cancer oral drug T-1201 received Phase I IND approval by the Taiwan FDA to conduct Phase I clinical trial.
Following IND approval by the US FDA in Mid-January, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on January 29 and received approval on April 12. The anticipated initiation of the Phase I trial remains by middle of 2021. T-1201 Phase I trial is a multi-centered study in Taiwan, …